NEWS HIGHLIGHTS
Published Studies Related to Proscar (Finasteride)
Change in sexual function in men with lower urinary tract symptoms/benign
prostatic hyperplasia associated with long-term treatment with doxazosin,
finasteride and combined therapy. [2014] Inventory during 4 years... CONCLUSIONS: This study significantly extends understanding of the effects of
Long-term effects of doxazosin, finasteride, and combination therapy on quality
of life in men with benign prostatic hyperplasia. [2013] International Prostate Symptom Score [IPSS]-QoL) over 4 years... CONCLUSIONS: QoL of men treated with doxazosin, finasteride, and
Long-term effects of doxazosin, finasteride and combination therapy on quality of
life in men with benign prostatic hyperplasia. [2013] International Prostate Symptom Score-QoL) during 4 years... CONCLUSIONS: The quality of life of men treated with doxazosin, finasteride, and
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide
vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. [2013] preventive agents in patients with CaP... CONCLUSION: This exploratory study establishes that karyometric monitoring can
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). [2011.08] OBJECTIVE: * To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months... CONCLUSION: * Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q(max) and urinary symptoms associated with BPH in men with an enlarged prostate. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
Clinical Trials Related to Proscar (Finasteride)
A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy [Completed]
The purpose of this study is to assess whether six months of daily finasteride (PROSCAR),
following an initial negative prostate biopsy, will improve the detection of prostate cancer
on repeat biopsy.
144 subjects with an initial negative prostate biopsy will be randomized to receive either
finasteride or placebo for 6 months. The subjects will undergo a second prostate biopsy
following drug intervention. PSA (prostate specific antigen) measurements, testosterone
levels, and quality of life questionnaires will also be assessed during the study. The two
groups will then be compared.
Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions [Completed]
The objective of this study was to evaluate the relative bioavailability of the test
formulation of finasteride 5 mg tablets (Dr. Reddy's Laboratories Limited) with the
reference formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.)under fasting conditions in
healthy adult male subjects.
Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions [Completed]
The objective of this study was to evaluate the relative bioavailability of the test
formulation of finasteride 5 mg tablets (Dr. Reddy's Laboratories Limited) with the
reference formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.)under fed conditions in
healthy adult male subjects.
3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer [Recruiting]
The investigators will propose a novel method to improve prostate cancer screening with PSA,
using a 3-month treatment with finasteride, a drug used to treat Benign Prostatic
Hyperplasia (BPH) and proven to reduce a man's risk of developing prostate cancer. The
investigators will also examine three additional promising tests that may further improve
diagnosis of prostate cancer.
Finasteride for Chronic Central Serous Chorioretinopathy [Terminated]
Background:
- Central serous chorioretinopathy (CSC) is a disease that causes fluid to collect under
the retina. It affects the macula, which is in the center of the retina and is needed
for sharp, clear vision. In many cases, CSC resolves on its own and does not need
treatment. However, in some cases it does not go away or comes back after treatment.
This is known as chronic CSC.
- Chronic CSC may be caused by hormones called androgens. Finasteride is a drug that can
alter the effects certain of androgens. Researchers want to compare finasteride with a
placebo to see if it is a safe and effective treatment for chronic CSC.
Objectives:
- To see if finasteride is a safe and effective treatment for chronic CSC.
Eligibility:
- Individuals at least 18 years of age who have chronic CSC in one or both eyes.
Design:
- Participants will be screened with a physical exam and medical history. A full eye exam
will be performed. Blood and urine samples will also be collected.
- Some participants may have photodynamic therapy (PDT), the standard treatment for CSC.
PDT helps to reduce the amount of fluid in the eye. Participants will need to wait for
3 months after PDT before starting the finasteride study.
- Participants will be separated into two groups. One group will take finasteride 5 mg
(formulated into capsules); the other group will take a placebo capsule. All
participants will take the capsules for 3 months.
- After 3 months on the assigned capsule (finasteride or placebo), all participants will
have the opportunity to take finasteride for at least another 4 years and 9 months.
This phase of the study is optional.
- Participants will have regular study visits. At each visit, they will have physical
exams and eye exams. They will also provide blood and urine samples.
- During the first 3 months, participants will have 2 study visits. After 3 months, if
the participant continues in the optional (or as needed) phase of the protocol, visits
will occur at Month 6, Month 12 and every 12 months thereafter. However, additional
visits may be needed.
Reports of Suspected Proscar (Finasteride) Side Effects
Anxiety (61),
Intentional Drug Misuse (53),
Depression (48),
Wrong Technique in Drug Usage Process (43),
Erectile Dysfunction (43),
Libido Decreased (40),
Sexual Dysfunction (38),
Fatigue (33),
Asthenia (33),
Back Pain (24), more >>
|